Stifel resumed coverage of Revolution Medicines (RVMD) with a Buy rating and $85 price target The firm sees Revolution being “on the cusp of majorly disrupting” the standard of care in pancreatic ductal adenocarcinoma and expects other indications to follow in years to come, calling the overall total addressable market “massive.” The firm models first revenue for Revolution in Q1 of 2027 and global revenue of $11.3B by 2035, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Erasca initiated with a Buy at Stifel
- 3 Stocks Flashing Strong Buy Alerts, According to Technical Analysis
- Revolution Medicines appoints Alan Sandler as CDO
- Revolution Medicines: Strategic Positioning and Promising Phase 3 Trials Drive Buy Rating
- Revolution Medicines price target raised to $71 from $70 at JPMorgan